Alytas Therapeutics GmbH was incorporated in 2018 as a spin-off of the University of Jena and is based in Jena, Germany. Its founders are experts in lipid-associated metabolic disorders and associated co-morbidities (like obesity).

Alytas Therapeutics GmbH aims to develop immunological therapy concepts for the treatment of adiposity(pathological obesity). This condition represents an unmet medical need and is one of the largest global social burdens caused by humans. Therapeutic antibodies for the treatment of obesity target one of the world's largest indications. The company believes that it has the relevant expertise on various antigen epitopes with proven relevance to novel therapeutic immunological regulation of excessive amounts of adipocytes in patients with obesity.

Given the current epidemic growth of obesity worldwide and its devastating associated co-morbidities, there is high demand for innovative, sustainable, and non-surgical forms of therapy for obesity with an acceptable side- effect profile and improved efficacy. Alytas Therapeutics GmbH’s project in this regard is a novel treatment form of obesity that makes use of anti-adipocyte antibodies and their immune mediated reduction of fat cells. This project is managed by Alytas Therapeutics GmbH in close cooperation with the University Hospital (Universitätsklinikum) Jena. The current treatment hypothesis of Alytas is based on in-vitro and in-vivo data from humans and animals.

In January 2020, Alytas Therapeutics GmbH has entered into an exclusive licence agreement with Velabs Therapeutics GmbH (now Veraxa Biotech AG) for the development and commercialization of Alytas’ antibodies in the field of senescence related degenerative processes and pathologies.

For more information, please visit: https://alytas.com/

‍